Weightlifting may be safe for women who fear lymphedema

Share this article:

Weightlifting may not increase lymphedema risk among breast-cancer survivors, according to the results of a 1-year intervention among female survivors at risk for breast cancer-related lymphedema (BRCL).  

Although most breast-cancer survivors do not have lymphedema, they alter the use of their arms and upper-body activities for fear of developing the condition, point out Kathryn H. Schmitz, PhD, MPH, of the University of Pennsylvania School of Medicine and Abramson Cancer Center, and colleagues, in their JAMA writeup (http://jama.ama-assn.org/content/early/2010/12/03/jama.2010.1837.full.pdf+html). “The findings from our trial should help clarify clinical advice to patients who have completed breast-cancer treatment regarding the safety of resuming or beginning a weightlifting program,” they state.

A total of 134 women, aged 36 to 75 years, completed the trial and 1-year follow-up measures. All had been diagnosed with breast cancer 1 to 5 years prior to study enrollment, had had at least two lymph nodes removed, and had no clinical signs of BCRL at the start of the program. Those randomized to the weightlifting intervention received a gym membership and 13 weeks of supervised instruction plus 9 months of unsupervised instruction. The control group did not exercise.

Thirteen (17%) of the 75 nonexercisers experienced new-onset BCRL, compared with only eight (11%) of the 72 weightlifters. The difference was even more marked among women who had had five or more lymph nodes removed: 11 (22%) of 49 in the control group experienced incident BCRL, compared with 3 (7%) of 45 in the intervention group. Dr. Schmitz and coauthors point out that their findings as well as previously published results involving women with BRCL suggest that all breast-cancer survivors should be able to partake in the health benefits of weightlifting.

In addition to appearing in JAMA, details of the study will be presented at the San Antonio Breast Cancer Symposium (www.sabcs.org), being held December 8-12, 2010.

 


 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

New analysis method finds possible therapeutic targets for drug resistant melanoma

Researchers have developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma.

Fewer cardiac scans in low-risk childhood cancer survivors can safely reduce costs ...

A less frequent screening schedule would both reduce health care charges and still protect low-risk childhood cancer survivors from heart ailments caused by drug therapy, according to recently published findings.

Everolimus does not improve overall survival of advanced liver cancer

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.